Tim Springer (Harvard)
With Moderna windfall, Harvard professor and integrins legend Tim Springer donates $210M to his Institute for Protein Innovation
Tim Springer, with his name stapled to the likes of Moderna, Scholar Rock and Editas Medicine, plus the foundational work for Takeda’s ulcerative colitis and Crohn’s disease med Entyvio, has had a lot on his plate over the past five decades.
In 2020, the Harvard professor became a billionaire thanks to early investing in Moderna and having profited a couple hundred million earlier in his career off his company LeukoSite’s sale to Millennium Pharmaceuticals before the turn of the century.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters